Q-omics provides the consensus-scored CCDC187 profile across patient tissues and cancer cell-line models. CCDC187 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CCDC187 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, CCDC187 RNA expression shows 14,636 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, KICH, and TGCT as cancer lineages where CCDC187 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC187 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC187 survival associations across molecular data types. CCDC187 RNA expression shows survival associations in the most cancer types (23), followed by mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC187 RNA expression–survival associations across cancer types. High CCDC187 expression shows unfavorable associations in KIRC, COAD and KIRP, but favorable associations in SKCM, READ and ACC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CCDC187 RNA expression.
This table summarizes CCDC187 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CCDC187. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC187 shows lower tumor expression in KICH and LUSC and higher tumor expression in COAD, BRCA, LIHC and STAD. The KICH box plot shows higher CCDC187 RNA expression in normal versus tumor tissue (log2 FC = −0.511, t-test p < 0.001).
This table shows molecular features associated with CCDC187 in patient tissues and cancer cell lines. In patient samples, CCDC187 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC187 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SKIN.
